KFAS
RCUS icon

Keating Financial Advisory Services’s Arcus Biosciences RCUS Stock Holding History

Keating Financial Advisory Services’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.16K Hold
135
– – ﹤0.01% 1639
2026
Q1 		$2.92K Buy
+135
New +$2.92K ﹤0.01% 1697

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Keating Financial Advisory Services's RCUS Position: Q2 2026 in Review

Keating Financial Advisory Services held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 135 shares worth $4.16K. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

Keating Financial Advisory Services first reported a position in RCUS in Q1 2026 and has held it in 2 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Keating Financial Advisory Services held 135 shares of Arcus Biosciences worth $4.16K as of Q2 2026.
  • Keating Financial Advisory Services left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1639 holding.
  • Keating Financial Advisory Services first reported a position in Arcus Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.